We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current CYDY market cap is 137.13M. The company's latest EPS is USD -0.0815 and P/E is -1.72.
| Year End May 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 266k | 0 |
| Operating Income | -55.85M | -74.65M | -104.6M | -71.91M | -40.58M |
| Net Income | -56.19M | -124.4M | -154.67M | -210.82M | -79.82M |
| Year End May 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 20.87M | 50.51M | 132.08M | 29.19M | 11.29M |
| Total Liabilities | 29.79M | 52.99M | 153.1M | 123.58M | 120.79M |
| Total Equity | -8.91M | -2.48M | -21.02M | -94.4M | -109.5M |
| Year End May 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -50.47M | -68.8M | -117.57M | -77.72M | -25.11M |
| Investing | -46k | -41k | -122k | N/A | N/A |
| Financing | 52.75M | 79.67M | 137.35M | 48.01M | 29.93M |
| Market Cap | 137.13M |
| Price to Earnings Ratio | -1.72 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 53.85 |
| Price to Book Ratio | -1.25 |
| Dividend Yield | - |
| Shares Outstanding | 979.53M |
| Average Volume (1 week) | 1.86M |
| Average Volume (1 Month) | 1.51M |
| 52 Week Change | -56.42% |
| 52 Week High | 0.418 |
| 52 Week Low | 0.1275 |
| Spread (Intraday) | 0 (1.43%) |
| Company Name | CytoDyn Inc (QB) |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.cytodyn.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
